A
Arcoscreen provides a primary‑cell GPCR screening platform that enables pharmaceutical developers to assess drug activity directly in mammalian cells derived from living tissue. The service combines a novel biological assay with a microfluidic chip, delivering in‑vitro data that better predicts in‑vivo outcomes. This accelerates the transition from early research to clinical trial candidate selection.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Arcoscreen provides a primary‑cell GPCR screening platform that enables pharmaceutical developers to assess drug activity directly in mammalian cells derived from living tissue. The service combines a novel biological assay with a microfluidic chip, delivering in‑vitro data that better predicts in‑vivo outcomes. This accelerates the transition from early research to clinical trial candidate selection.